secwatch.observer — SEC 8-K summary
======================================

Issuer:     10x Genomics, Inc. (TXG)
CIK:        0001770787
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0001770787-24-000015
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

10x Genomics Q4 revenue up 18% to $184M but net loss widens to $49M; FY2024 guidance 8-12% growth
--------------------------------------------------------------------------------

- Q4 2023 revenue $184.0M (+18% YoY); FY2023 revenue $618.7M (+20% YoY).
- Q4 gross margin 63% vs 76% YoY due to higher mix of Spatial instruments.
- Q4 operating loss $55.2M (vs $23.1M), including $38.9M stock-based comp and $19.6M in-process R&D expense.
- Full year 2023 net loss $255.1M, widened from $166.0M in 2022.
- FY2024 revenue guidance $670M-$690M (8-12% growth); cumulative instruments sold reached 5,966.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770787/000177078724000015/0001770787-24-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770787/000177078724000015/txg-20240215.htm
  HTML page:      https://secwatch.observer/filing/0001770787-24-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer